Biodesix Announces Selecting of Ryan Siurek as Chief Accounting Officer – Press Launch

BOULDER, Colo.–(Company Wire)–Biodesix, Inc. (Nasdaq: BDSX), a top facts-pushed diagnostic remedies enterprise with a concentration in lung disorder, these days introduced that Ryan Siurek has joined the firm as Main Accounting Officer reporting to Ms. Robin Harper Cowie, Main Financial Officer.

“I am very happy to welcome Ryan as our new Chief Accounting Officer. His substantial finance and accounting leadership experience will assist Biodesix develop as we enter our up coming phase of improvement in 2021 and over and above,” stated Ms. Cowie.

Prior to becoming a member of the Firm, Mr. Siurek served as Senior Vice President, Main Accounting Officer and Controller of Vail Resorts, Inc. from April 2016 to September 2020. From January 2009 to April 2016, Mr. Siurek served as an government at Dash Corporation where he held numerous accounting and finance roles including Vice President Controller & Main Accounting Officer and Vice President, Divisional Main Economical Officer for the pay as you go and wholesale and business options divisions. Mr. Siurek gained a BBA & MS in Accounting from Texas A&M University, and is a Accredited Community Accountant. Mr. Siurek also serves as a member of the American Institute of Licensed Community Accountants (AICPA) Fiscal Reporting Executive Committee (FinREC), a senior committee concentrated on financial reporting.

About Biodesix

Biodesix is a major diagnostic firm with a target in lung condition. The Business develops diagnostic checks addressing significant medical issues by combining multi-omics as a result of the electrical power of artificial intelligence. Biodesix is the to start with organization to provide six non-invasive tests for sufferers with illnesses of the lung. Biodesix introduced the SARS-CoV-2 ddPCR™ exam and the Platelia SARS-CoV-2 Whole Ab in reaction to the international pandemic and virus that impacts the lung and causes COVID-19. The blood-primarily based Biodesix Lung Reflex® approach for lung most cancers people integrates the GeneStrat® and VeriStrat® exams to assist treatment method selections with benefits in 72 hours, expediting time to procedure. The blood-centered Nodify Lung™ nodule danger assessment screening approach, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the threat of malignancy in incidental pulmonary nodules, enabling medical professionals to superior triage patients to the most proper training course of motion. Biodesix also collaborates with a lot of of the world’s main biotechnology and pharmaceutical firms to solve advanced diagnostic challenges in lung illness. For extra information about Biodesix, go to biodesix.com.

Be aware With regards to Forward-Seeking Statements

This press launch could incorporate ahead-on the lookout statements that require substantial hazards and uncertainties for needs of the protected harbor provided by the Personal Securities Litigation Reform Act of 1995. All statements contained in this push launch other than statements of historical reality, are ahead-looking statements. The text “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and equivalent expressions are meant to discover ahead-wanting statements. This kind of statements are centered on management’s recent anticipations and require risks and uncertainties. Real outcomes and performance could differ materially from all those projected in the forward-wanting statements as a consequence of several aspects. Biodesix has based these ahead-hunting statements largely on its present expectations and projections about foreseeable future functions and developments. These forward-seeking statements are matter to a number of pitfalls, uncertainties and assumptions. Also, Biodesix operates in a competitive and quickly changing surroundings. New risks arise from time to time. It is not possible for its administration to forecast all hazards, nor can it evaluate the affect of all variables on its organization or the extent to which any aspect, or combination of components, may bring about genuine benefits to vary materially from all those contained in any forward-seeking statements it may perhaps make. Biodesix undertakes no obligation to revise or publicly release the effects of any revision to these kinds of ahead-wanting statements, apart from as expected by regulation. Presented these challenges and uncertainties, viewers are cautioned not to spot undue reliance on this kind of ahead-looking statements. All ahead-searching statements are qualified in their entirety by this cautionary assertion.

Jordona Jackson Smith

Jordona@jacksonbio.com

805-674-7347